Merz Therapeutics GmbH
- Address
- Eckenheimer Landstrasse 100, Nordend West
Sponsor Overview
Specializations
Headache Disorders
Clinical research includes prevention-focused studies in episodic migraine and chronic migraine, with attention to reducing migraine burden and improving symptom control in affected adults.
- Chronic migraine
- Episodic migraine
- Monthly migraine days
The sponsor’s work in this area is centered on injectable therapies evaluated for migraine prevention across both episodic and chronic forms of the disorder.
Neuropathic Pain
Another key area is moderate to severe chronic peripheral neuropathic pain, including pain associated with postherpetic neuralgia and peripheral nerve injury, where research is directed toward relief of persistent pain symptoms.
- Peripheral neuropathic pain
- Postherpetic neuralgia
- Peripheral nerve injury
These studies reflect interest in conditions with ongoing sensory pain and functional impact in adult patients.
Injectable Neuromodulatory Therapies
The portfolio includes research on botulinum toxin-based injections used in neurological and pain-related disorders, with clinical interest spanning both migraine prevention and neuropathic pain management.
- Xeomin
- NT 201
- Injection-based treatment
This therapeutic domain links neurology and pain medicine through locally administered treatment approaches.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A parallel-group treatment, proof-of-concept Phase 2, multicenter, double-blind, randomized 2 arm clinical trial to investigate the efficacy and safety of subcutaneous NT 201 injections compared with placebo injections in decreasing pain intensity in male and female participants aged 18 years and older with moderate or severe chronic neuropathic pain due to postherpetic neuralgia or peripheral nerve injury. |  Bulgaria France Germany Hungary Poland Spain | Not Recruiting |
| Efficacy and Safety Evaluation of Clostridium Botulinum Neurotoxin Type A in Chronic Migraine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial |  Austria Czechia Denmark France Germany Italy Poland Slovakia Spain | Recruiting |
| Efficacy and Safety Evaluation of Clostridium Botulinum Neurotoxin Type A in Episodic Migraine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial | Austria Czechia Denmark France Germany Italy Poland Slovakia Spain | Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 93 sites across their trial portfolio.
Therapeutic Focus
- 1.Nervous System Diseases3 trials449 other sponsors
Partnered Research Centres
93 centres- Address
- Ul. Fordonska 144, 85-752 Bydgoszcz
- Address
- Ostrovskeho 253/3, Smichov, 150 00 Prague
- Address
- Largo Giovanni Alessandro Brambilla 3, 50134 Florence
- Address
- Carrer De La Feixa Llarga S/N, 08907 L'hospitalet De Llobregat
- Address
- Uzsoki Utca 29-41, 1145 Budapest
- Address
- 2 Avenue Martin Luther King, 87000 Limoges
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Merz Therapeutics GmbH.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.